Ratings AddLife AB

Equities

ALIF B

SE0014401378

Market Closed - Nasdaq Stockholm 17:00:00 17/06/2024 BST 5-day change 1st Jan Change
126 SEK +1.20% Intraday chart for AddLife AB +4.22% +15.17%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company sustains low margins.
  • The company is in debt and has limited leeway for investment
  • With an expected P/E ratio at 63.89 and 34.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+15.17% 1.44B
C
+38.66% 53.67B
B-
+33.67% 38.86B
A
-7.81% 38.76B
B
-10.77% 27.27B
C
+11.77% 25.91B
B-
-17.82% 20.29B
B
+35.09% 12.78B
B+
+29.17% 12.18B
C+
-3.05% 11.96B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW